FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas

Recurrent genomic rearrangements in primary testicular lymphoma

(2015) David DW Twa et al.   JOURNAL OF PATHOLOGY

Converting mucus-making cells into mucus-clearing cells

(2015) Nancy R. Gough   Science Signaling

Converting mucus-making cells into mucus-clearing cells

(2015) Nancy R. Gough   Science Signaling

FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF- B to promote survival of human B cells

(2014) M. van Keimpema et al.   BLOOD

Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study

(2014) Wataru Yamamoto et al.   LEUKEMIA & LYMPHOMA

The transcription factor Foxp1 is a critical negative regulator of the differentiation of follicular helper T cells

(2014) Haikun Wang et al.   NATURE IMMUNOLOGY

Non-IG Aberrations of FOXP1 in B-Cell Malignancies Lead to an Aberrant Expression of N-Truncated Isoforms of FOXP1

(2014) Leila Rouhigharabaei et al.   PLoS One

Downregulation of FOXP1 is required during germinal center B-cell function

(2013) A. Sagardoy et al.   BLOOD

Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients

(2013) K K Wong et al.   LEUKEMIA

Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma

(2013) Soham Puvvada et al.   Cancer Genetics

CIITA and Its Dual Roles in MHC Gene Transcription

(2013) Ballachanda N. Devaiah et al.   Frontiers in Immunology

Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease

(2012) Bin Tang et al.   HUMAN MOLECULAR GENETICS

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

(2012) Tina Marie Green et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2012) C Visco et al.   LEUKEMIA

Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy

(2012) Jacques Thibodeau et al.   OncoImmunology

Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma

(2011) S. T. Wilkinson et al.   BLOOD

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

(2011) G. Salles et al.   BLOOD

Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1

(2011) V. J. Craig et al.   BLOOD

Bare lymphocyte syndrome: An opportunity to discover our immune system

(2011) Dilip Shrestha et al.   IMMUNOLOGY LETTERS

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

Malignant pirates of the immune system

(2011) Lixin Rui et al.   NATURE IMMUNOLOGY

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

(2010) G. Ott et al.   BLOOD

Aberrant expression of the neuronal transcription factorFOXP2in neoplastic plasma cells

(2010) Andrew J. Campbell et al.   BRITISH JOURNAL OF HAEMATOLOGY

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

(2009) W. W.L. Choi et al.   CLINICAL CANCER RESEARCH

CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression

(2009) L. M. Rimsza et al.   HAEMATOLOGICA

Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials

(2009) H.-W. Bernd et al.   HAEMATOLOGICA

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP

(2008) L. M. Rimsza et al.   BLOOD

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab

(2008) J-P Jais et al.   LEUKEMIA

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE